Formalization
The codification of endogenic pharmacology as a formal discipline. The proprietary technology, the patent portfolio, the distribution tiers, and the canonical reference.
From research literature to formal discipline.
By 2026, the body of evidence supporting short peptide bioregulation as a distinct pharmacological category was sufficient to support its formalization as a named discipline — with a defined scope, a codified taxonomy, and an institutional reference structure. Endogenic pharmacology is the formal name of that discipline. Bioregulatory medicine is its clinical practice. Bioregulators are its therapeutic class.
The codification rests on four foundational components: the proprietary Ac-X-NH2 dual-terminus modification enabling non-injectable bioregulator delivery; the eleven-application provisional patent portfolio filed March 2026; the two-tier opticeutical and endoceutical distribution architecture; and the canonical reference institution — this site — that consolidates the discipline's definitional, taxonomic, and bibliographic anchors.
What comes next.
From the formalization point forward, the discipline's trajectory tracks the standard pattern of pharmaceutical-science translation: continued mechanistic research, indication-specific efficacy and safety study, regulatory pathway navigation toward FDA-approved endoceutical preparations, and commercial-scale opticeutical distribution. The non-provisional patent filings due March 2027 will anchor the proprietary technology base for the first decade of clinical translation.
Endogenic pharmacology is, at its formalization, both old and new. It rests on five decades of established research. It begins, as a formal discipline, today.